The abstract is read at the publisher; the summary is JClub's.
GAK is a tumor-selective dependency in diffuse large B-cell lymphoma, and its kinase activity is required for mitotic progression, with inhibition causing G2/M arrest and cell death.
- Why it matters: Many approved kinase inhibitors yield only transient or no responses in DLBCL, and most kinases remain poorly characterized, motivating phenotypic screening plus machine learning to find actionable targets.
- What they did: The study screened a probe library across DLBCL systems spanning pathogenic heterogeneity and used iterative target-deconvolution analysis (idTRAX) to identify tumor-selective kinases, then tested GAK mechanistically and with inhibitors in vivo.
- The result: GAK inhibition increased anti-DLBCL efficacy in the absence of the retinoblastoma (RB) tumor suppressor, and GAK-directed inhibitors, including repurposed clinical compounds, showed promising single-agent activity in vivo.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.